Ranjan Maity

Utilizing PROTAC technology to address the on-target platelet toxicity associated with inhibition of BCL-X _L

Curcumin, the golden nutraceutical: multitargeting for multiple chronic diseases

Proteolysis targeting chimeras (PROTACs) are emerging therapeutics for hematologic malignancies

Hepatocellular carcinoma

Discovery of PROTAC BCL-XL degraders as potent anticancer agents with low on-target platelet toxicity

ilastik: interactive machine learning for (bio)image analysis

Thymoquinone and its therapeutic potentials

Advances in genome editing through control of DNA repair pathways

Proteasomal and lysosomal degradation for specific and durable suppression of immunotherapeutic targets

Cancer Cell Signaling Pathways Targeted by Spice-Derived Nutraceuticals

Genome editing with CRISPR–Cas nucleases, base editors, transposases and prime editors

Inflammation-Induced Cell Proliferation Potentiates DNA Damage-Induced Mutations In Vivo

Tel1 and Rif2 Regulate MRX Functions in End-Tethering and Repair of DNA Double-Strand Breaks

PROTAC targeted protein degraders: the past is prologue

Anti-cancer effects of thymoquinone in mouse neuroblastoma (Neuro-2a) cells through caspase-3 activation with down-regulation of XIAP

Microhomology-Mediated End Joining: A Back-up Survival Mechanism or Dedicated Pathway?

NF-κB, inflammation, immunity and cancer: coming of age

Multiple cereblon genetic changes are associated with acquired resistance to lenalidomide or pomalidomide in multiple myeloma

Simultaneous precise editing of multiple genes in human cells

Evolution of Cereblon-Mediated Protein Degradation as a Therapeutic Modality

DNA Double-Strand Break Repair Pathway Choice Is Directed by Distinct MRE11 Nuclease Activities

Capsaicin induces apoptosis through ubiquitin–proteasome system dysfunction

Breast Cancer Proteins PALB2 and BRCA2 Stimulate Polymerase η in Recombination-Associated DNA Synthesis at Blocked Replication Forks

From Inhibition to Degradation: Targeting the Antiapoptotic Protein Myeloid Cell Leukemia 1 (MCL1)

Cereblon Splicing of Exon 10 Mediates IMiDs Resistance in Multiple Myeloma: Clinical Validation in the CoMMpass Trial